Novocure Shares Climb After Company Posts Higher 1Q Revenue, Raises Full-Year Outlook

Dow Jones05-01

By Christopher Kuo

Novocure shares soared after the company posted double-digit first-quarter revenue growth and raised its full-year revenue outlook.

Shares of the oncology company climbed 27% on Thursday to $15.20. The company's shares are up 17% year to date.

The company raised its full-year revenue guidance. It now expects revenue of $690 million to $710 million. Analysts polled by FactSet are expecting full-year revenue of $698.9 million.

The company reported a loss of $71.1 million, or 62 cents a share, compared with a loss of $24.3 million, or 31 cents a share a year earlier. Analysts expected a loss per share of 51 cents.

Revenue rose 12% to $174.1 million, driven by active patient growth in European markets. Analysts expected revenue of $167.8 million.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

April 30, 2026 12:56 ET (16:56 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2632652726?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-01 00:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632652726","market":"hk","top_or_hot":-1,"title":"Novocure Shares Climb After Company Posts Higher 1Q Revenue, Raises Full-Year Outlook","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Novocure shares soared after the company posted double-digit first-quarter revenue growth and raised its full-year revenue outlook. \n</p>\n<p>\n  Shares of the oncology company climbed 27% on Thursday to $15.20. The company's shares are up 17% year to date. \n</p>\n<p>\n  The company raised its full-year revenue guidance. It now expects revenue of $690 million to $710 million. Analysts polled by FactSet are expecting full-year revenue of $698.9 million. \n</p>\n<p>\n  The company reported a loss of $71.1 million, or 62 cents a share, compared with a loss of $24.3 million, or 31 cents a share a year earlier. Analysts expected a loss per share of 51 cents. \n</p>\n<p>\n  Revenue rose 12% to $174.1 million, driven by active patient growth in European markets. Analysts expected revenue of $167.8 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 30, 2026 12:56 ET (16:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novocure Shares Climb After Company Posts Higher 1Q Revenue, Raises Full-Year Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovocure Shares Climb After Company Posts Higher 1Q Revenue, Raises Full-Year Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-01 00:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Novocure shares soared after the company posted double-digit first-quarter revenue growth and raised its full-year revenue outlook. \n</p>\n<p>\n  Shares of the oncology company climbed 27% on Thursday to $15.20. The company's shares are up 17% year to date. \n</p>\n<p>\n  The company raised its full-year revenue guidance. It now expects revenue of $690 million to $710 million. Analysts polled by FactSet are expecting full-year revenue of $698.9 million. \n</p>\n<p>\n  The company reported a loss of $71.1 million, or 62 cents a share, compared with a loss of $24.3 million, or 31 cents a share a year earlier. Analysts expected a loss per share of 51 cents. \n</p>\n<p>\n  Revenue rose 12% to $174.1 million, driven by active patient growth in European markets. Analysts expected revenue of $167.8 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 30, 2026 12:56 ET (16:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVCR","symbol_name":"NovoCure Limited","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2632652726","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2632652726","pubTimestamp":1777568160,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Novocure shares soared after the company posted double-digit first-quarter revenue growth and raised its full-year revenue outlook.Shares of the oncology company climbed 27% on Thursday to $15.20. The company's shares are up 17% year to date.The company raised its full-year revenue guidance. It now expects revenue of $690 million to $710 million. Analysts polled by FactSet are expecting full-year revenue of $698.9 million.The company reported a loss of $71.1 million, or 62 cents a share, compared with a loss of $24.3 million, or 31 cents a share a year earlier. Analysts expected a loss per share of 51 cents.Revenue rose 12% to $174.1 million, driven by active patient growth in European markets. Analysts expected revenue of $167.8 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVCR":"NovoCure Limited","BK4588":"碎股","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4082":"医疗保健设备","BK4548":"巴美列捷福持仓"},"translate_title":"Novocure公布第一季度营收增加并上调全年预期后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":0.9},"content_text":"By Christopher Kuo \n\n\n \n\n\n  Novocure shares soared after the company posted double-digit first-quarter revenue growth and raised its full-year revenue outlook. \n\n\n  Shares of the oncology company climbed 27% on Thursday to $15.20. The company's shares are up 17% year to date. \n\n\n  The company raised its full-year revenue guidance. It now expects revenue of $690 million to $710 million. Analysts polled by FactSet are expecting full-year revenue of $698.9 million. \n\n\n  The company reported a loss of $71.1 million, or 62 cents a share, compared with a loss of $24.3 million, or 31 cents a share a year earlier. Analysts expected a loss per share of 51 cents. \n\n\n  Revenue rose 12% to $174.1 million, driven by active patient growth in European markets. Analysts expected revenue of $167.8 million. \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 30, 2026 12:56 ET (16:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2632652726","isCrawlerRequest":true}